

新北市呼吸治療師公會

Taipei County Respiratory Therapist Association

講師資料卡

姓 名：王秉槐

現職單位：亞東紀念醫院 內部科 副主任

E - mail：pinghuaiwang@gmail.com

學 歷：台灣大學醫學系

經 歷：

亞東紀念醫院胸腔內科 主治醫師

陽明交通大學醫學系助理教授

亞東科技大學護理系講師

專 長：

內科學、胸腔醫學

著 作：

1. **Wang PH**, Kuo PH, Chang YC, Yang PC. CASE FOR DIAGNOSIS A patient with right upper quadrant abdominal pain, hypotension and dyspnoea. *Eur Respir J* 2002; 20: 238-241
2. **Wang PH**, Kuo PH, Hsu CL, Wu HD, Chang YS, Kuo SH, Yang PC. Diagnostic value of negative expiratory pressure for airway hyperreactivity. *Chest* 2003; 124: 1762-7
3. **Wang PH**, Yu CJ, Wu HD, Yang PC. High-frequency oscillatory ventilation in adult patients with acute respiratory distress syndrome plus air-leak syndrome. *Thoracic Med* 2003; 18: 419-26
4. **Wang PH**, Shih KS, Tsai CC, Wang HC. Pulmonary tuberculosis with delayed infection of total knee arthroplasty: A case report. *J Formos Med Assoc.* 2007; 106: 82-5
5. **Wang PH**, Wang HC, Cheng PW, Cheng SL, Tsai CC. Hoarseness in an asthmatic patient: the side effect of inhaled steroid or not? *J asthma* 2007; 44: 823-6
6. **Wang PH**, Wang HC, Tsai CC. Estrogen replacement in female lung cancer during gefitinib therapy. *Jpn J Clin Oncol* 2009; 39(12): 829-832

7. **Wang PH**, Cheng SL, Wang HC, Chang HT, Hsu YL, Chen YS, CY Chang. Systemic steroid in acute exacerbation of COPD-from guideline to bedside. *Int J Clin Pharmacol Ther*. 2011 Nov;49(11):705-8.
8. **Wang PH**, Wang HC, Huang TW. Tuberculous otitis media without lung Involvement And the risk of airborne transmission. *J Formos Med Assoc*. 2013;112:497-8
9. **Wang PH**, Wang HC, Cheng SL. Airway Bacterial Colonization in COPD under the Therapy of Inhaled Corticosteroid/long-acting β 2 Agonist- the Relationship with COPD Assessment Test. *J Intern Med Taiwan* 2013;24:487-94
10. **Wang PH**, Wang HC, Liao CH. Disseminated *Penicillium marneffei* Mimicking Paradoxical Response and Relapse in a non-HIV Patient with Pulmonary Tuberculosis. *J Chin Med Assoc* 2015;78:258-60
11. Chang CH, **Wang PH**, Chang HT. Pulmonary nocardiosis in a non-HIV patient: a case report. *Thoracic Med* 2015;30:30-5
12. Lin CC, **Wang PH**. Intravenous glycyrrhizin improved serum transaminases rapidly in a chronic hepatitis B patient with acute exacerbation *J Formos Med Assoc*.2015; 114:188-9
13. Wang CJ, **Wang PH**. Disseminated *Mycobacterium kansasii* infection in a non-human immunosuppressive virus (HIV) patient without immunosuppressive therapy *Thoracic Med* 2016;31:169-75
14. **Wang PH**, Wang HC, Cheng SL, Liao CH. Selection of empirical antibiotics for health-care associated pneumonia via integration of pneumonia severity index and risk factors of drug-resistant pathogens. [*J Formos Med Assoc*. 2016;115:356-63](#)
15. **Wang PH**, Wang HC. Risk factors to predict drug-resistant pathogens in hemodialysis-associated pneumonia. *BMC Infectious Diseases* 2016 16(1) DOI: 10.1186/s12879-016-1701-1
16. Lin CH, **Wang PH**, Kuo YW, Ho CC. Equal efficacy of Gefitinib in chemonaïve lung adenocarcinoma patients with either Exon19 deletion or L858R mutation. *Thorac Med* 2017; 32: 14-23
17. **Wang PH**. The association of temperature and PM2.5 with exacerbations of adult chronic airway disease in small urban region of northern Taiwan. *Thoracic Med* 2018; 33: 139-148
18. Shu CC, Wu SH, Wu MF, Lai HC; **Wang PH (corresponding)**, Cheng SL, Wang JY, Yu CJ. Mono- and poly-functional T cells in nontuberculous mycobacteria lung disease patients: Implications in analyzing risk of disease progression. *Cytokine* 2019;120: 176-85
19. **Wang PH**, Pan SW, Shu CC, Chen CY, Wei YF, Cheng SL, Wang HC, Yu CJ. Clinical course and risk factors of mortality in *Mycobacterium avium* complex lung disease without initial treatment. *Resp Med* 2020; 171:106070.

20. **Wang PH**, Lin CH, Chang TH, Wu CS. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients. *BMC Pulm Med* 2020; **20**: 232 <https://doi.org/10.1186/s12890-020-01274-9>
21. **Wang PH**, Lin SY, Lee SJ, Lin SW, Lee CY, Wei YF, Shu CC, Wang JY, Yu CJ. CD4 response of QuantiFERON-TB Gold Plus for positive consistency of latent tuberculosis infection in patients on dialysis. *Sci Rep* 2020; **10**: 2136.
22. Lin SY, Feng JY, Lee CY, Lin YC, Chou YH, Lin KY, Wei YF, Lin SW, Chang CH, **Wang PH** (co-corresponding), Shu CC, Wang YJ, Yu CJ. Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: predictors and impacts of different regimens in a prospective cohort study. *Antimicrob Agents Chemother* 2021; 65(3): e02184-20.
23. Lee, CT., **Wang, PH**. Handgrip strength during admission for COPD exacerbation: impact on further exacerbation risk. *Journal of Biomaterials Applications* 2021; 35(10): 1355-1365
24. **Wang PH**, Wu MF, Hsu CY, Lin SY, Chang YN, Lee HS, Wei YF, Shu CC. The Dynamic Change of Immune Checkpoints and CD14+ Monocytes in Latent Tuberculosis Infection. *Biomedicines*. 2021; 9(10):1479.
25. **Wang PH**, Wu MF, Hsu CY, Pan SW, Shu CC, Cheng SL. The trend of TIM3 expression on T cells in patients with nontuberculous mycobacterial lung disease: from immune cell dysfunction to clinical severity. *Front Immunol* 2021; 12: 738056. doi: 10.3389/fimmu.2021.738056
26. **Wang PH**, Gow CH, Chiu YL, Li TC. Determination of Low Muscle Mass by Muscle Surface Index of the First Lumbar Vertebra Using Low-Dose Computed Tomography. *J. Clin. Med.* 2022, 11,2429.
27. **Wang PH**, Pan SW, Wang SM, Shu CC, Chang CC. The impact of nontuberculous mycobacteria species on mortality in patients with nontuberculous mycobacterial lung disease. *Front Microbiol.* 2022 Jul 7;13:909274. doi: 10.3389/fmicb.2022.909274
28. Tsou HH, **Wang PH (co-1st)**, Ting TH, Ping YH, Liu TY, Cheng HW, Wang HT. Effect of heated tobacco products and traditional cigarettes on pulmonary toxicity and SARS-CoV-2-induced lung injury. *Toxicology* 2022; 479: 153318.
29. Hsieh YH, Chang HT, **Wang PH**, Chang MY, Hsu HS. Mortality in patients with COVID-19 versus non-COVID-19- related acute respiratory distress syndrome: A single center retrospective observational cohort study. *PLoS ONE* 2023; 18(6): e0286564. <https://doi.org/10.1371/journal.pone.0286564>
30. **Wang PH**, Lin SY, Liou HH, Chen CC, Shu CC, Lee CY, Tsai MK, Yu CJ. Protective Effect of BCG and Neutrophil-to-Lymphocyte Ratio on Latent Tuberculosis in End Stage Renal Disease. *Infect Dis Ther.* 2023 Jul 6. doi: 10.1007/s40121-023-00839-5.
31. Chang LK, **Wang PH**, Lee TF, et al. Microbiological persistence in patients

with Mycobacterium abscessus complex lung disease: The prevalence, predictors, and the impact on progression. *Int J Infect Dis.* 2023; 15:S1201-9712(23)00778-6

32. **Wang PH**, Shu CC, Chen CY, Wei YF, Cheng SL. The role of treatment regimen and duration in treating patients with Mycobacterium avium complex lung disease: A real-world experience and case-control study, *J Microbiol Immunol Infect.* 2024; 57:164-74 doi: 10.1016/j.jmii.2023.11.006.
33. **Wang PH**, Shu CC, Sheu CC, Chang CL, Hsieh MH, Hsu WH, et al. Clinical Predictors of Nontuberculous Mycobacteria Lung Disease and Coisolates of Potential Pathogenic Microorganisms in Noncystic Fibrosis Bronchiectasis. *Open Forum Infect Dis.* 2024 Jul 18;11(8):ofae427. doi: 10.1093/ofid/ofae427
34. **Wang PH**, Wei YF, Liu CJ, Chen CY, Lin SW, Pan SW, Wang SM, Shu CC, Chang CH, Yu CJ. The therapeutic impact of maximum chemotherapy possession days during three consecutive months in non-tuberculous mycobacterial lung disease: A real-world experience. *J Microbiol Immunol Infect.* 2025